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This article provides an overview of the problem of genetic susceptibility to childhood cancer
with a particular emphasis on problems with ascertaining inherited cancer risk and the role of
tumor-suppressor gene mutations in cancer predispositions. The association between
neurofibromatosis type 1 and childhood leukemia is used to illustrate some of the issues faced by
molecular biologists and genetic epidemiologists in identifying and analyzing at-risk individuals.
The problem of incomplete penetrance in cancer susceptibility is presented and potential models
are discussed. The article concludes with a number of tentative conclusions from existing data
and speculations for future studies. Environ Health Perspect 106(Suppl 3):801-806 (1998).
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Introduction
Ifidentifying genetic susceptibilities is an
important challenge facing cancer epidemi-
ologists, particular attention and effort
should be directed to childhood cancer.
Although inherited cancer syndromes were
estimated to account for only 0.1% ofall
malignant neoplasms (1), a known genetic
predisposition was observed in 4.2% of
pediatric cases (2). As new genes and more
complex patterns ofinheritance and pene-
trance are uncovered, the proportion of
both childhood and adult cancers arising in
patientswith aknown constitutional suscep-
tibility will undoubtedly rise over the next
few years. This article begins with a brief
overview ofinherited cancer susceptibilities.
I then use the association between neurofi-
bromatosis type 1 (NF1) and myeloid
leukemia as an example ofa low penetrance
cancer predisposition, discuss a few general




The notion that a particular disorder is
genetic in origin usually refers to the fact
that it is transmitted within families.
Although some human cancers are herita-
ble genetic disorders, most patients have no
known susceptibility to cancer, and malig-
nant transformation results from a series of
somatic mutations in a target cell. Cancer
is therefore unique, in that acquired
(somatic) genetic alterations play a major
role in its pathogenesis. Many of these
genetic alterations are induced by environ-
mental mutagens such as ultraviolet radia-
tion, cigarette smoke, and industrial toxins.
In some families, the predisposition to
develop cancer is transmitted from parent
to child, and children with germline muta-
tions of cancer susceptibility genes are at
high risk ofdeveloping specific malignant
tumors. Familial cancer syndromes have
been extraordinarily informative for defin-
ing general mechanisms of tumorigenesis
and for discovering the responsible genes.
In addition, many ofthe genes that confer
a genetic predisposition to childhood
cancer play a central role in normal cellular
growth control.
Classes ofCancerSusceptibility Genes
A number ofdistinct genetic mechanisms
have been implicated in inherited cancer
predispositions including a) mutations of
cellular protooncogenes, b) germline inacti-
vation ofboth alleles of a recessive gene,
c) gross chronmosomal abnormalities, and
d) germline inactivation ofone allele ofa
tumor-suppressor gene. The single example
of a dominant oncogenic mutation that is
associated with a human cancer syndrome
involves RETgene mutations in multiple
endocrine neoplasia type 2 (3). Some auto-
somal recessive disorders carry an increased
cancer risk including xeroderma pigmento-
sum, ataxia telangiectasia, and Fanconi ane-
mia. In these patients, malignant clones
arise as a result ofacquired mutations at
cooperating loci. Down and Turner syn-
dromes are examples ofconstitutional chro-
mosomal abnormalities that are associated
with an increased risk ofspecific cancers.
Although all ofthese disorders are ofgeneral
biologic interest, the overall impact ofthese
three genetic mechanisms on cancer inci-
dence is small. In contrast, germline inacti-
vation of one allele of tumor-suppressor
genes accounts for the majority ofheritable
human cancer risk (4-6). I will therefore
focus on this class ofgenes in the remainder
ofthis article.
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Tumor-Suppressor Genes
In 1971, Knudson developed a hypothesis
to explain the peculiar epidemiology of
retinoblastoma, a rare malignant eye tumor
ofchildhood. This genetic model predated
the development of recombinant DNA by
5 years. Clinically, children with retino-
blastoma fall into two categories: a group
with early onset disease characterized by
frequent bilateral involvement and by an
autosomal dominant pattern ofinheritance
in many families, and a second group that
shows later onset, unilateral disease, and a
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negative family history. According to
Knudson's model, children in the group
with early onset, heritable retinoblastoma
were at markedly increased risk of cancer
because all of their somatic cells carry an
inactive copy ofa gene that plays a central
role in regulating the growth ofimmature
retinal cells (first hit). An acquired mutation
ofthe single normal allele in any susceptible
cell (second hit) inactivates the gene and
contributes to the development ofcancer.
Thus, the Knudson model postulates that
both alleles oftumor-suppressor genes must
be inactivated by separate events during
tumorigenesis. Because every somatic cell
contains the first hit, patients with germline
mutations of tumor-suppressor genes
develop cancer at a relatively young age and
are prone to multiple independent tumors.
Although loss ofgrowth control is recessive
at the cellular level, the cancer predisposi-
tion is transmitted as a dominant trait, with
offspring having a 50% chance ofinheriting
the predisposing mutant allele from an
affected parent. The Knudson model also
correctly predicted that the same tumor-
suppressor genes would be involved in the
pathogenesis ofnonfamilial cases ofcancer.
In these patients, both copies ofthe tumor-
suppressor gene are affected by independent
somatic mutations. Inactivation oftumor-
suppressor genes occurs by various genetic
mechanisms including structural deletions,
point mutations, or gene conversion.
Human tumor-suppressor genes identified
to date include RBI (retinoblastoma,
osteosarcoma), W7TJ (Wilms tumor), p53
(Li-Fraumeni syndrome), NFI (neural crest
tumors, childhood leukemia), NF2(acoustic
neurofibroma, meningioma), APC (colon
cancer), and the breast cancer susceptibility
genes BRCAI and BRCA2. An interesting
group of genes that have recently been
implicated in human tumorigenesis encode
proteins involved in DNA mismatch repair.
Although many investigators argue that
these hMUTgenes define a new class of
cancer susceptibility genes because oftheir
novel biochemical properties, they behave
genetically like tumor-suppressors (i.e., at-
risk individuals inherit a single mutant allele
in the germline and the malignant clone
inactivates the normal copy).
MolecularAnalysis
The identification oftumor-suppressor genes
has been problematic because ofthe techni-
cal difficulty in finding genes that are inacti-
vated during tumorigenesis. For this reason,
most ofthe existing tumor-suppressor genes
were identified by reverse genetics; that is,
their protein products were only known
after the gene was cloned by ascertaining
the position of the gene by linkage.
Analysis of tumor specimens for loss of
constitutional heterozygosity (LOH) has
provided a powerful tool for localizing
human tumor-suppressor genes to specific
chromosomal regions. The underlying
principle is simple. Somatic inactivation of
tumor-suppressor genes is frequently
caused by structural deletions ofDNA and
this, in turn, can be detected by finding
that a heterozygous locus in normal tissues
is reduced to homozygosity in the tumor.
This principle is illustrated in Figure 1.
The recent availability of a set ofhighly
polymorphic microsatellite markers has
provided powerful tools for the studies of
LOH and for linkage analysis in affected
families. Once a tumor-suppressor gene has
been cloned, a variety oftechniques exists
to analyze specimens from cancer-prone
families for mutations including Southern
blotting, single-strand conformational
polymorphism analysis, protein truncation
testing, and DNA sequencing. Caution
must be exercised in the use ofthese meth-
ods; in addition to issues ofprivacy and
confidentiality, it may be difficult to ascer-
tain if nucleotide substitutions in tumor-
suppressor genes represent true mutations
or polymorphisms (7,8). Recently, targeted
homologous recombination into murine
embryonic stem cells has proven invaluable
in characterizing how tumor-suppressor
genes function in both normal develop-
ment and in tumorigenesis (9).
Penetrance,PhenotypicVariability,
andGeneticHeterogeneity
Individuals with germline RB] mutations
represent perhaps the ideal constellation of
clinical and molecular characteristics for
ascertaining cancer susceptibility. First, the
penetrance of retinoblastoma is greater
than 90% in individuals with these muta-
tions. This means that affected families will
show a clear dominant pattern of inheri-
tance that can be used to reliably score
individuals with respect to carrier status.
Second, because retinoblastoma is cured in
a majority ofcases, manyaffected individu-
als reproduce and this provides pedigrees
for analysis. Third, children with germline
mutations of RBI often show a distinctive
phenotype of early onset and bilateral
involvement that distinguishes them for
patients without such alterations. This has
proven to be particularly useful in identify-
ing children who are likely to show de novo













Figure 1. LOH analysis in tumor specimens by analysis
of polymorphic microsatellite markers consisting of
variable nucleotide tandem repeats. Top panel:
Noncoding (intronic) sequences in human DNA fre-
quently contain stretches of short tandemly repeated
DNA sequences such as CA. Because the number of
repeats is highly variable between individuals, these
sequences provide excellent polymorphic markers for
genetic linkage and LOH studies. Oligonucleotide
primers are designed which flankthe repeat on interest
and the repeat is amplified and labeled using the poly-
merase chain reaction. In this illustration, allele A con-
tains five CA repeats and allele B contains three. This
results in a four-nucleotide difference in the size ofthe
amplified fragment which is easily resolved on a
sequencing-type gel. Bottom panel: In this ideal family,
the filled in squares indicate that the son has inherited
a tumor-suppressor gene that predisposes to cancer
from his father. Amplification using oligonucleotide
primers that detect a polymorphic marker at the dis-
ease locus reveals a larger fragment from one of the
father's chromosomes (labeled B) and a shorter Cfrag-
ment. The repeats amplifed from maternal chromo-
somes are slightly longer (A) and shorter (D) that the
paternal alleles. The son has inherited a mutant B
allele from his affected father and an abnormal copy of
the gene from his mother (D). Deletion of the normal
maternal allele of this tumor-suppresor gene during
tumorigenesis results in LOH atthe locus.
inactivation of RBI is a consistent finding
in both familial and sporadic retinoblas-
toma tumors. In summary, retinoblastoma
is a particularly well-behaved tumor from
the standpoint of genetic epidemiology
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because it shows a high degree ofpene-
trance, is frequently curable, gives a consis-
tent phenotype, and shows limited genetic
heterogeneity. As discussed below, as these
characteristics deviate from this ideal
situation, identifying individuals who inherit
cancer susceptibilities and discovering the
tumor-suppressor genes that are mutated
in the germline becomes progressively
more complicated.
NFl andChildhoodLeukemia
Neurofibromatosis type 1 (NF1) is a
common autosomal dominant disorderwith
an incidence ofapproximately 1 in 3500
(10). Affected individuals are predisposed to
specific benign and malignant neoplasms
that primarily arise from cells ofneural crest
origin. These tumors include neurofibro-
mas, neurofibrosarcomas, optic gliomas, and
pheochromocytomas (10). Young children
with NF1 have a 200- to 500-fold excess
incidence ofmalignant myeloid disorders,
particularly juvenile myelomonocytic
leukemia UMML) (formally known as juve-
nile chronic myelogenous leukemia) and
monosomy 7 syndrome (Mo 7) (11-14).
Interestingly, adults with NFl do not
appear to be at increased risk ofleukemia.
In 1990, the NFI gene was identified inde-
pendently in the laboratories of Francis
Collins and Ray White (15-17). Almost
immediately thereafter, a computer-based
sequence alignment showed that NFI con-
tains a domain with significant homology to
yeast and mammalian GTPase-activating
proteins (GAPs) (18,19). GAPs negatively
regulate the biochemical output ofcellular
Ras proteins by accelerating conversion of
Ras from its active guanosine triphosphate-
bound conformation (Ras-GTP) to its inac-
tive guanosine diphosphate-bound state
(Ras-GDP) (20). Activating point muta-
tions ofRASprotooncogenes are among the
most common molecular alterations seen in
human cancer cells, including myeloid
leukemias [reviewed in Bos (21) and
Rodenhuis (22)]. Taken together, the find-
ing ofactivating RAS mutations in many
human tumors, biochemical evidence that
neurofibromin negatively regulates Ras-
GTP, and the increased cancer riskobserved
in individuals with NF1 suggested that NFI
might function as a tumor-suppressor gene.
This hypothesis predicts that the single nor-
mal NFI allele will be inactivated during
tumorigenesis in individuals with NF1.
Indeed, LOH at has been detected in neu-
rofibrosarcomas (23-25), pheochromocy-
tomas (26), and neurofibromas (27) from
patients with NF1.
Wehavebeenworkingto understand the
molecular basis of the increased risk of
leukemia seen in children with NF1. We
first showed that their bone marrows fre-
quently acquired LOH at the NFl locus
(28,29). In children with familial NFI, the
copy ofthe NFI gene that was inherited
from the unaffected parent was invariably
deleted in the leukemia, whereas the copy
from the parentwith NF1 was retained. This
result is consistent with the Knudson model.
To ascertain ifboth copies ofthe NFI gene
were functionally inactive in these leukemias
and to ask ifspecific germline mutations
were associated with a strong risk ofcancer,
we adapted a coupled in vitro transcription/
translation assay to screen for mutations that
lead to premature termination ofprotein
translation, and then performed DNA
sequencing to confirm suspected mutations.
These studies revealed nine different NFI
gene mutations, all ofwhich are predicted to
destroy protein function. The bone mar-
rows offive patients with these truncating
NFI mutations also showed LOH at NFl
and have therefore inactivated both NFl
alleles (30). These findings prove that NFl
functions as a tumor-suppressor gene in
childhood leukemia.
The data presented above are consistent
with the proposal that neurofibromin (the
protein encoded by the NFl gene) nega-
tively regulates the growth ofmyeloid cells
byacting as a GAP for Ras. This model pre-
dicts that acquired RAS mutations will be
restricted to children who do not have NFI
because an oncogenic Ras protein would be
biochemically redundant in cells with defec-
tive neurofibromin GAP activity. We and
our collaborators tested this hypothesis in
children with malignant myeloid disorders
and found activating RASmutations in 15
of72 samples from children without NFl
but in 0 of 19 patients with NF1 (p=0.02)
(31,32). These genetic data suggesting that
neurofibromin restrains the growth of
immature myeloid cells by regulating Ras
were further supported by biochemical
experiments showing that the leukemic cells
ofchildren with NFl show a reduction in
neurofibromin-associated GAP activity and
increased levels ofRas-GTP (33). A final
line ofevidence that NFl functions as a
tumor-suppressor gene in immature
hematopoietic cells is derived from experi-
ments performed in mice inwhich one copy
of the murine NFI gene (Nfl) was dis-
rupted by targeted homologous recombina-
tion (34,35). Heterozygous Nfl mice
(Nfl+l-) are phenotypically normal; how-
ever, these animals are predisposed to
pheochromocytoma and myeloid leukemia
(35). Molecular investigation has shown
loss of the wild-type Nfl allele in the
murine leukemias studied to date, a finding
that parallels our experience in children
with NFI. Nfl-l- embryos die in utero by
day 13 ofgestation from developmental
abnormalities ofthe cardiopulmonary sys-
tem (34,35). However, fetal liver cells
from NFi-l- embryos have been used to
reconstitute hematopoiesis in irradiated
recipients. Mice transplanted with Nf-l-
cells consistently develop a syndrome remi-
niscent of JMML characterized by a
marked overproliferation ofmyeloid cells
that infiltrate the spleen and liver (36).
In addition to the predilection to
primary malignant tumors of the central
nervous system, rhabodomyosarcomas,
fibrosarcomas, and myeloid leukemia,
recent data suggest that children with NF1
who are successfully treated with muta-
genic agents are at high risk ofdeveloping
second malignant neoplasms. We have
investigated five such patients who devel-
oped secondary leukemia with Mo 7 after
being treated with multimodal therapy for
other cancers (37). Each received alkylat-
ing agents as part of their initial cancer
therapy. Our collaborator John Maris also
reviewed the Tumor Registry at the
Children's Hospital of Philadelphia and
found an incidence of second cancer of
10% in children with NFI. Of eight
patients with embryonal cancers (neurob-
lastoma, Wilms tumor, or rhabdomyosar-
coma), six developed a second cancer (37).
This is perhaps due to the fact that these
young children typically receive aggressive
multimodal therapy that includes both
chemotherapy and radiation.





Of 509 children with cancer identified in
the study of Narod et al. (2), four major
genetic associations accounted for 90% of
the cases: bilateral retinoblastoma (162
patients), Down syndrome (135 patients),
NFl (90 patients), and hereditary forms of
Wilms tumor (70 patients). I believe that
these associations represent the tip of the
iceberg with respect to the true influence
of genetic factors in childhood cancer.
Retinoblastoma and some cases ofWilms
tumor follow a classic pattern ofautosomal
dominant inheritance with high penetrance.
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The remaining Wilms tumor patients and
children with Down syndrome or NFl
show characteristic physical findings.
These observations suggest that it will be
difficult to ascertain heritable cancer risk if
only a small proportion of affected indi-
viduals develop a specific cancer (incom-
plete penetrance) or if at risk individuals
do not show characteristic phenotypic
findings. NF1 is an interesting case in
point. The best epidemiologic study of
cancer risk in NF1 estimated a relative
risk of 2.5 in affected individuals fol-
lowed in Denmark for over 40 years (38).
Similarly, in a comprehensive survey of
the Japan Children's Cancer Registry,
Matsui et al. (39) found that dispro-
portionate numbers ofchildren with NF1
developed neurofibrosarcoma, optic
glioma, rhabdomyosarcoma, and myeloid
leukemia. However, although the relative
risk of all of these malignant neoplasms
was greatly increased, the absolute risk was
generally small. For example, the overall
population-based risk ofrhabdomyosar-
coma has been estimated to be 4.5 cases
per million per year (40) and the data of
Matsui suggests that this is 54-fold higher
in children with NFl. However, this
translates to an risk of 243 cases per mil-
lion children with NFl (0.02%). Because
the penetrance of rhabdomyosarcoma is
very low in children with NFl, it is highly
unlikely that this relationship would be
known if NF1 were not associated with a
set ofdiagnostic physical features. Similar
arguments apply to myeloid leukemia in
children with NF1 or Down syndrome.
Individuals with NF1 illustrate another
potentially problematic aspect ofinherited
cancer susceptibility: alterations of the
same gene may predispose to many differ-
ent tumors. Unlike patients who inherit
germline RBI or APC mutations and
almost invariably develop a specific type of
cancer as the initial malignant tumor,
individuals with NFl are at risk for a
range of different cancers. Li-Fraumeni
syndrome (LFS) is perhaps the best-known
example of an inherited tumor-suppressor
gene alteration that is associated with a
spectrum ofdifferent tumor types. With
p53 gene mutations now well established as
the predominant cause of LFS, families
with atypical clinical findings (including
variable penetrance) have been identified.
Furthermore, screening studies ofpatients
with LFS-associated tumor types have
revealed individuals with germline p53





There are a number of potential models
that might explain variable clinical expres-
sion of inherited cancer predispositions.
The first and most likely is that homozy-
gous inactivation of most tumor-suppressor
genes represents an important step in
tumorigenesis but is not sufficient for full
malignant transformation. Colon cancer is
the best-characterized example ofmultistep
tumorigenesis; in that system two known
heritable cancer genes (APCand p53) are
frequently mutated in both familial and
sporadic cases (44). The leukemias ofchil-
dren with NF1 not only inactivate the nor-
mal copy of NFl, but frequently show
deletions of chromosome 7 (13,45). In
addition, epigenetic factors such as the sex
ofthe parent transmitting NF1 and the sex
ofthe affected child also appear to modu-
late the risk ofleukemia (13,29). These
observations suggest that the relatively low
penetrance ofchildhood leukemia in chil-
dren with NF1 is because additional genetic
lesions are required in addition to loss of
NFI gene function. A second potential
explanation for relatively low penetrance is
that specific tumor-suppressor gene muta-
tions differ with respect to the associated
cancer risk. There is limited evidence in
support ofthis model. For example, certain
families with a low penetrance pattern of
retinoblastoma inheritance show mutations
in the RBI promoter that presumably do
not completely abrogate gene transcription
(46). A final genetic mechanism to explain
variable penetrance is that interacting
genetic factors strongly influence the clini-
cal expression of many inherited cancer
susceptibilities. A strong influence ofcoop-
erating loci has been shown clearly in mice
which carry germ line mutations ofAPC
(47-50). With respect to NF1, two lines of
evidence argue strongly that specific NFI
mutations are not associated with a high
incidence ofchildhood leukemia. First,
although we have investigated over 25
affected children (many with siblings who
have NFI), none has had a first-degree rela-
tive with leukemia. Second, each of the
mutations that we have identified in
leukemic cells are expected to abrogate neu-
rofibromin function and none has previ-
ously been associated with cancer. On the
other hand, one study suggested that coop-
erating loci may modulate the severity of
nonmalignant NFl-associated compli-
cations (51). How inherited mutations of
tumor-suppressor genes cooperate with
other genetic factors such as alterations in
the levels ofenzymes that detoxify environ-
mental carcinogens is an important area of
ongoing investigation in human beings and
in animal models.
SecondMalignantTumors
A feature ofinherited cancer predispositions
that has received limited attention is that
susceptible individuals are notonly at risk of
developing an initial cancer, but also second
malignant neoplasms (SMNs). Two broad
categories of SMN can be distinguished:
neoplasms that arise in prior radiation fields
or in patients who previously received sys-
temic mutagenic chemotherapy, and a sec-
ond primary de novo cancer that does not
appear to be related to the previous malig-
nancy or its treatment. Although ascertain-
ing the relative contributions of treatment
and of a possible inherited susceptibility to
the development ofSMN is not straightfor-
ward in patients who have been exposed to
mutagenic therapies, it appears that individ-
uals with germline mutations ofRBI, p53,
and NFI are each at increased risk of
developing SMN (5,37,52). As myeloid
leukemia is one ofthe most common types
ofSMN overall (53) it is not surprising that
it accounts for a significant proportion of
SMNs that occur in children with NFl
(37). We recently used heterozygous Nfl
knockout mice to directly demonstrate an
interaction between chemotherapeutic
agents that alkylate DNA and germline
inactivation ofNfl in leukemogenesis (54).
Conclusions and Implications
for Epidemiologic Studies
I close with a few thoughts that might be
relevant to epidemiologists with an interest
in childhood cancer.
I believe that we have only seen the tip
ofthe iceberg with respect to the influence
ofgenetic predispositions on the develop-
ment ofchildhood cancer. Uncovering the
submerged hunk ofthe iceberg poses a for-
midable task for genetic epidemiologists
and molecular biologists because the
underlying genetic alterations are likely to
show incomplete penetrance and will prob-
ably not be associated with a constellation
ofknown clinical syndromes.
On the basis ofwhat we nowknow, it is
likely that germline inactivation oftumor-
suppressor genes will account for most
inherited cancer predispositions that will be
discovered in the future. Individuals who
inherit a mutation ofone allele ofa given
suppressor gene will likely be especially
susceptible to environmental mutagens.
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Interactions between different genetic
loci, as well an environmental factors,
will likely be important in determining
which patients with inherited genetic sus-
ceptibilities actually develop cancer, what
type of cancer appears, and the age at
disease onset.
Many ofthe cancer predispositions that
remain to be discovered will probably be
similar to LFS and NF1 in that they will
show awide range oftissue expression.
Patients who develop second malignant
neoplasms may prove a valuable resource
for uncovering new cancer susceptibilities.
With respect to discovering new cancer
susceptibility genes, there is both good
news and bad news. The good news is that
the experimental methodologies and
genomic resources available for the posi-
tional cloning of tumor-suppressor genes
are vastly better than even a few years
ago-good news for molecular biologists.
The bad news is that the tumor-suppressor
genes that remain to be discovered will
almost certainly behave badly in that they
will be less penetrant, show less tissue
specificity, and will not be associated with
a constellation of characteristic physical
findings to readily identify at risk individu-
als-bad news for genetic epidemiologists.
All of this is succinctly summarized in a
recent review by King (55).
Given this complexity and the immense
technical, ethical, legal, and insurance
issues that surround testing people for
genetic susceptibilities to cancer, it is clear
that studies need to be planned and con-
ducted very carefully with appropriate
review. Multidisciplinary teams of com-
mitted investigators are required for this
important task.
I would emphasize the central role of
genetic epidemiologists who are not molec-
ular biologists in a) recognizing subtle
and/or complex cancer predispositions,
b) identifying at risk families and assem-
bling pedigrees and biologic specimens,
c) developing strategies to investigate mod-
ifying genetic and environmental factors
that affect cancer risk, and d) generating
testable hypotheses.
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